Header cover image

Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

UpdatedFeb 11, 2025
DataAggregated Company Financials
Companies9
  • 7D15.8%
  • 3M21.2%
  • 1Y25.8%
  • YTDn/a

The Clinical Research and Equipment industry is up 16% in the last week, with WuXi Biologics (Cayman) up 8.7%. In the same time, Frontage Holdings was down 5.9%. This takes the industry's 12 month performance to a gain of 26%. Looking forward, earnings are forecast to grow by 42% annually.

Industry Valuation and Performance

Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 11 Feb 2025HK$180.9bHK$35.7b-HK$1,061,504,029.7057.5x-170.5x5.1x
Thu, 09 Jan 2025HK$147.8bHK$35.6b-HK$1,060,958,629.1656.2x-139.3x4.2x
Sat, 07 Dec 2024HK$154.8bHK$35.9b-HK$1,058,516,453.3254.1x-146.2x4.3x
Mon, 04 Nov 2024HK$153.9bHK$35.7b-HK$660,755,913.7438x-232.9x4.3x
Wed, 02 Oct 2024HK$175.6bHK$36.1b-HK$650,693,031.7735.4x-269.9x4.9x
Fri, 30 Aug 2024HK$125.6bHK$36.1b-HK$786,730,453.7225.9x-159.6x3.5x
Sun, 28 Jul 2024HK$90.7bHK$33.5bHK$3.1b16.8x29.4x2.7x
Tue, 25 Jun 2024HK$92.2bHK$33.4bHK$3.1b20.6x30x2.8x
Thu, 23 May 2024HK$102.3bHK$33.5bHK$3.1b30.5x33.1x3.1x
Sat, 20 Apr 2024HK$104.7bHK$33.6bHK$3.1b32.5x33.8x3.1x
Mon, 18 Mar 2024HK$120.3bHK$33.3bHK$3.7b47.6x32.7x3.6x
Wed, 14 Feb 2024HK$124.0bHK$32.3bHK$3.0b46.7x41.7x3.8x
Fri, 12 Jan 2024HK$198.5bHK$32.4bHK$3.0b91.8x66.3x6.1x
Sun, 10 Dec 2023HK$208.4bHK$32.3bHK$3.0b81.4x69.7x6.4x
Tue, 07 Nov 2023HK$272.9bHK$30.2bHK$2.7b47.7x101.4x9x
Thu, 05 Oct 2023HK$245.6bHK$30.2bHK$2.7b41.7x91.8x8.1x
Sat, 02 Sep 2023HK$235.0bHK$30.3bHK$2.7b41.8x86.9x7.7x
Mon, 31 Jul 2023HK$236.8bHK$28.5bHK$2.7b23.8x86.2x8.3x
Wed, 28 Jun 2023HK$209.3bHK$28.4bHK$2.7b21.2x77x7.4x
Fri, 26 May 2023HK$235.8bHK$28.9bHK$2.8b21.9x83.6x8.1x
Sun, 23 Apr 2023HK$265.7bHK$29.5bHK$2.9b25.1x90.5x9x
Tue, 21 Mar 2023HK$238.6bHK$26.4bHK$2.1b22.9x115.6x9x
Thu, 16 Feb 2023HK$313.3bHK$26.5bHK$2.1b25.1x149.5x11.8x
Sat, 14 Jan 2023HK$378.5bHK$26.7bHK$2.2b27.6x174.2x14.2x
Mon, 12 Dec 2022HK$288.2bHK$26.0bHK$2.0b27.9x144.4x11.1x
Wed, 09 Nov 2022HK$255.7bHK$25.6bHK$1.9b24.8x137.4x10x
Fri, 07 Oct 2022HK$256.4bHK$25.7bHK$1.9b20.5x134.5x10x
Sun, 04 Sep 2022HK$343.4bHK$26.3bHK$2.1b27.3x167.1x13x
Tue, 02 Aug 2022HK$384.6bHK$22.3bHK$2.1b12x187.6x17.2x
Thu, 30 Jun 2022HK$379.0bHK$22.4bHK$2.1b15.6x182.6x16.9x
Sat, 28 May 2022HK$284.4bHK$22.3bHK$2.1b13.1x138.4x12.7x
Mon, 25 Apr 2022HK$296.8bHK$22.9bHK$2.2b14.3x133.1x12.9x
Wed, 23 Mar 2022HK$314.7bHK$19.2bHK$1.5b21.1x205.9x16.4x
Fri, 18 Feb 2022HK$350.8bHK$18.7bHK$2.8b24.4x124.3x18.7x
Price to Earnings Ratio

124.3x


Total Market Cap: HK$350.8bTotal Earnings: HK$2.8bTotal Revenue: HK$18.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Clinical Research and Equipment Industry Price to Earnings3Y Average 58x202320242025
Current Industry PE
  • Investors are pessimistic on the Hong Kong Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 8.4x is higher than the industry's current PS ratio of 5.1x.
Past Earnings Growth
  • Total earnings for the Life Sciences Tools and Services industry have declined over the last three years, with the industry now making a loss overall.
  • Meanwhile revenues have grown 24% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Hong Kong Clinical Research and Equipment compare with similar industries?

HK Market4.44%
Healthcare7.16%
Life Sciences15.84%
Clinical Research and Equipment15.84%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
2269 WuXi Biologics (Cayman)HK$21.408.7%
+HK$7.0b
23.6%PE31.2x
2228 XtalPi HoldingsHK$6.7024.5%
+HK$4.5b
n/aPS108.6x
2576 Zhejiang Taimei Medical TechnologyHK$5.0558.8%
+HK$1.1b
n/aPS4.6x
2268 WuXi XDC CaymanHK$29.202.6%
+HK$898.7m
99.5%PE55.2x
1873 Viva Biotech HoldingsHK$0.9419.0%
+HK$316.8m
51.6%PS0.9x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

2576

HK$5.05

Zhejiang Taimei Medical Technology

7D

58.8%

1Y

n/a

6118

HK$0.59

Austar Lifesciences

7D

3.5%

1Y

-70.2%

2268

HK$29.20

WuXi XDC Cayman

7D

2.6%

1Y

99.5%

2228

HK$6.70

XtalPi Holdings

7D

24.5%

1Y

n/a

8225

HK$0.19

China Health Group

7D

7.3%

1Y

29.7%

1521

HK$1.60

Frontage Holdings

7D

-5.9%

1Y

-7.5%